Two new Phase III studies of Xarelto (Bayer HealthCare) initiated for AF patients scheduled for surgery

Bayer HealthCare has initiated two new studies investigating Xarelto (rivaroxaban) in patients with Atrial Fibrillation who are scheduled for cardioversion or first catheter ablation. X-VeRT is the largest randomised study dedicated to evaluating patients with AF scheduled for cardioversion. It will include approximately 1,500 patients across 17 countries worldwide, including the UK. The study will further examine the efficacy and safety profile of Xarelto to prevent cardiovascular events, including stroke, in comparison to dose-adjusted vitamin K antagonist. VENTURE-AF will evaluate the safety profile of Xarelto in patients with non-valvular AF undergoing first catheter ablation, in 200 patients across five countries, including the UK. X-VeRT and VENTURE-AF complement the Phase III ROCKET AF study, where once-daily rivaroxaban was proven to be effective in preventing stroke and non-CNS (central nervous system) systemic embolism in patients with non-valvular AF.